Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gelesis, Inc.

https://www.gelesis.com/

Latest From Gelesis, Inc.

SPAC Mergers Are Viable Funding Tools, But The Test Is Yet To Come

Dozens of health care-focused special purpose acquisition corporations have gone public during the past two years but many biopharma firms that have merged with SPACs have not performed well to date, raising the question of how long the SPAC boom will last.

Deals Financing

Finance Watch: The Bigger The Better? Erasca, Imago Rise After IPOs

Public Company Edition: Three $100m-plus US initial public offerings launched on 15 July after two smaller biopharma IPOs earlier in the month. Also, Gelesis announced a SPAC merger, Brii and Amniotics launched ex-US IPOs, and Intellia, Cerevel and Kymera priced large follow-on offerings. 

Financing Growth

Hub-And-Spoke Pioneer PureTech's Strategy Paying Off

The concept of a parent company with operating subsidiaries is becoming increasing common in biotech. The first to do it, Daphne Zohar, who co-founded PureTech back in 2005, tells Scrip how the company has made that model work.

Companies Strategy

Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area

Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.

Deals Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Biomaterials
UsernamePublicRestriction

Register